BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life Sciences Category at the ninth annual NEVY Awards by the New England Venture Capital Association (NEVCA). The awards recognize and celebrate the top innovators, investors and companies in the region. The theme this year highlighted the “heroes” of New England’s innovation ecosystem—the entrepreneurs and investors committed to leveraging science and technology for a better tomorrow. Presented again this year by Dell Technologies, winners were announced both live and in-person at House of Blues Boston and streamed virtually. 

“Dyno has a pioneering artificial intelligence (AI) led approach to solving gene therapy’s biggest challenge: the efficient, safe and precise gene delivery to target tissues,” said Eric Kelsic, PhD, chief executive officer and co-founder of Dyno Therapeutics. “We are honored to receive this recognition from NEVCA as Emerging Company of 2021 for the Life Sciences. Thanks to all AAViators for making this possible  through Collective Innovation: empowering a  diverse team of the best problem solvers to drive cutting-edge science towards improving patient health.” 

The NEVYs honor both early- and late-stage companies, as well as the venture capitalists who support them, and cover a broad spectrum of the region’s thriving industry clusters. The academies are broken out across Life Sciences, Healthcare, Climate Tech, MedTech and Technology.

“It was wonderful to celebrate our NEVYs award ceremony both in-person and virtually to honor the heroic companies and investors working to fortify the innovation in New England and beyond,” said NEVCA President, Jody Rose. “Those in our venture community are building a brighter and bolder future for all of us. Congratulations to the winners and nominees!”

Dyno Therapeutics joins an impressive list of outstanding companies from around New England, in categories across the innovation landscape.

The winners of the 2021 NEVY Awards in the Life Sciences category are:

  • Patient Impact Award: Moderna
  • Emerging Life Science Company of the Year: Dyno Therapeutics
  • Life Science Deal of the Year: Pandion Therapeutics

The winners of the 2021 NEVY Awards in the Healthcare category are:

  • Emerging Healthcare Company of the Year: FOLX Health
  • Powerhouse Healthcare Company of the Year: Reify Health
  • Liquidity Event of the Year: Iora Health

The winners of the 2021 NEVY Awards in the MedTech category are:

  • Emerging MedTech Company of the Year: PanTher Therapeutics
  • Powerhouse MedTech Company of the Year: Vicarious Surgical

The winners of the 2021 NEVY Awards in the Climate Tech category are:

  • Early Company of the Year: Sublime Systems
  • Powerhouse Climate Tech Company: Desktop Metal
  • Rocket Ship Company of the Year: Battery Resources

The winners of the 2021 NEVY Awards in the Technology category are:

  • Emerging Tech Company: Verve Motion
  • Hottest Tech Startup: Perch
  • Liquidity Event of the Year: Toast
  • Company of the Year: Whoop

The winner of the 2021 NEVY Awards Fund of the Year was: Bessemer Venture Partners

Alongside Presenting Sponsor Dell Technologies, the 2021 NEVY Awards were supported by Abbvie, Alexandria Real Estate Equities, Deloitte, IDA Ireland, Johnson & Johnson Innovation – JJDC, JP Morgan, Matter and V2 Communications.

About Dyno Therapeutics
Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit for additional information.

About CapsidMap™ for Designing Optimized AAV Gene Therapies
Dyno’s CapsidMap™ platform overcomes the limitations of gene therapies on the market and under development today by optimizing capsids, the cell-targeting protein shells of Adeno-Associated Virus (AAV) vectors. Current gene therapies primarily use a small number of naturally occurring capsids that are limited by delivery efficiency, pre-existing immunity, payload size, and manufacturing challenges. CapsidMap works in two stages, first by measuring capsid properties in high-throughput using next-generation DNA library synthesis and DNA sequencing. With these vast quantities of in vivo data, CapsidMap then generates improved capsid sequences by applying advanced search algorithms that leverage machine learning. Dyno’s comprehensive map of capsid sequence space and AI‑powered tools thereby accelerate the design of AAV gene therapies towards optimizing manufacturability and applicability for treating a broader range of diseases.


About the New England Venture Capital Association
The New England Venture Capital Association (NEVCA) works toward a collaborative, inclusive, and prosperous innovation ecosystem. Through unique program-building, critical policy work, innovative regional marketing and dynamic local events, the NEVCA invests in the entrepreneurial ecosystem on behalf of the VC community. From celebrations (the NEVY Awards) to content series (VC Briefings and Syndicate Sessions), workforce development programs (Hack.Diversity and the Bioscience & Investor Inclusion Group) to advocacy and legislation (noncompete and immigration reform), the NEVCA is at once a network, catalyst and resource for the innovation economy.


Dyno Therapeutics PR Contact:

Nisha Deo
Head of Communications
Tel: +1 857 242-0593

Back to Top